Earnings summaries and quarterly performance for REVELATION BIOSCIENCES.
Executive leadership at REVELATION BIOSCIENCES.
Board of directors at REVELATION BIOSCIENCES.
Research analysts covering REVELATION BIOSCIENCES.
Recent press releases and 8-K filings for REVB.
Revelation Biosciences, Inc. Secures $7.3 Million Through Warrant Exercise Inducement
REVB
Debt Issuance
New Projects/Investments
- Revelation Biosciences, Inc. (REVB) entered into warrant exercise inducement offer letters on January 23, 2026, generating approximately $7.3 million in gross proceeds from the exercise of existing Class I Common Stock Warrants.
- Two holders exercised 2,136,251 post-split shares at an approximate exercise price of $3.44 per share, receiving 4,272,500 post-split new Class J Common Stock Warrants in exchange.
- The company intends to use the net proceeds for clinical development plans, working capital, and general corporate purposes.
- Roth Capital Partners, LLC will receive an 8% cash fee of the aggregate gross proceeds for financial advisory services.
Jan 28, 2026, 11:46 PM
RevBio Receives FDA Approval for Pivotal Clinical Trial of Cranial Flap Bone Glue
REVB
Product Launch
New Projects/Investments
- RevBio has received FDA Investigational Device Exemption (IDE) approval for a multi-center randomized controlled pivotal clinical trial of its TETRANITE® cranial flap bone glue.
- This trial, known as T-RESTORE II, represents the final development phase before commercial approval for TETRANITE®, which is designed to immediately fixate cranial flaps and enable bone fusion.
- The study will enroll up to 204 patients across up to 15 clinical sites, comparing TETRANITE® against standard cranial plate and screw systems.
- RevBio's CEO highlighted that this pivotal trial targets a $10 billion market for bone glue applications and marks the company's second active pivotal stage program.
Jan 28, 2026, 2:42 PM
Revelation Biosciences reaches agreement with FDA on Gemini approval pathway for AKI
REVB
New Projects/Investments
Product Launch
- Revelation Biosciences (REVB) announced an agreement with the FDA on the approval pathway for its drug candidate, Gemini, for Acute Kidney Injury (AKI).
- The agreed pathway involves a single, adaptive Phase 2/3 clinical study with a primary endpoint combining death and/or the need for dialysis.
- Positive data from this approximately 300-patient study will be sufficient for the submission of a New Drug Application (NDA).
- The company plans to initiate this pivotal Phase 2/3 study during 2026.
Jan 22, 2026, 12:01 AM
Revelation Biosciences Announces Q3 2025 Financial Results and Clinical Study Data
REVB
Earnings
New Projects/Investments
- Revelation Biosciences, Inc. reported a net loss of $1.9 million or $(1.77) per share for the three months ended September 30, 2025, and a net loss of $6.4 million or $(9.76) per share for the nine months ended September 30, 2025.
- As of September 30, 2025, the company had $12.7 million in cash and cash equivalents, which it believes is sufficient to fund operations through the third quarter of 2026.
- The company announced groundbreaking top-line results from its PRIME Clinical Study and received $9.6 million in gross proceeds from a warrant inducement in September 2025.
Nov 6, 2025, 9:28 PM
RevBio Receives FDA Approval for TETRANITE Clinical Trial
REVB
New Projects/Investments
- RevBio has received FDA approval for a 20-patient pilot study for its regenerative "bone glue" TETRANITE to treat complex, multi-fragmented wrist fractures.
- This approval expands the platform of indications for TETRANITE, which is currently in ten FDA approved clinical trials and is anticipated to receive De Novo classification for several key indications, expediting its path to commercialization.
- The TETRANITE platform is designed to address a total addressable market of over $10 billion in neurosurgical, orthopaedic, and dental use cases, but is not yet approved for commercial use.
Nov 4, 2025, 10:00 AM
Revelation Biosciences Announces $9.6 Million Gross Proceeds from Warrant Exercise
REVB
New Projects/Investments
- Revelation Biosciences Inc. announced the immediate exercise of certain outstanding warrants, generating $9.6 million in gross proceeds.
- The transaction involved the exercise of 4,355,000 shares of common stock at an exercise price of $2.20 per share.
- In consideration for the immediate cash exercise, the exercising holders will receive new Class I warrants to purchase up to 13,065,000 shares of common stock at an exercise price of $2.20 per share, exercisable for five years after stockholder approval.
- The company intends to use the net proceeds from the warrant exercises for its clinical development plans, working capital, and general corporate purposes.
Sep 15, 2025, 9:02 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more